A Study to Compare to PK Characteristics and Safety Profiles Between PA-111 and PA-111A

Phase 1 Recruiting 48 enrolled Addpharma Inc.

RandomizedCrossoverOpen-labelTreatment

Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of PA-111 in healthy subjects.

Evaluation	Drug	Modality	Dose	Route
Subject	PA-111	Unknown	—	Oral
Subject	PA-111A	Unknown	—	Oral